APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pneumonia Treatment Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Pneumonia Treatment Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025194 pages

Choose your research edition.

Industry ResearchPneumonia Treatment Drugs Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Pneumonia Treatment Drugs Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Pneumonia Treatment Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pneumonia Treatment Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Pneumonia Treatment Drugs Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Pneumonia Treatment Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Pneumonia Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pneumonia Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pneumonia Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Pneumonia Treatment Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pneumonia Treatment Drugs include Teva Pharmaceutical, Sun Pharmaceutical, Novartis, Mylan, Pfizer, GlaxoSmithKline, AstraZeneca, Theravance Biopharma and Shinogi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pneumonia Treatment Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pneumonia Treatment Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pneumonia Treatment Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pneumonia Treatment Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Pneumonia Treatment Drugs Segment by Company

Teva Pharmaceutical

Sun Pharmaceutical

Novartis

Mylan

Pfizer

GlaxoSmithKline

AstraZeneca

Theravance Biopharma

Shinogi

MSD

Medicines

Combioxin

Arsanis

Pneumonia Treatment Drugs Segment by Type

Vaccines

Vancomycin

Cephalosporin

Tetracyclines

Penicillin

Other Antibiotics

Immunotherapy Drug

Interferon

Fluoroquinolones

Macrolides

Pneumonia Treatment Drugs Segment by Application

Hospital

Clinic

Drugstore

Pneumonia Treatment Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumonia Treatment Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pneumonia Treatment Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumonia Treatment Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pneumonia Treatment Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pneumonia Treatment Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Pneumonia Treatment Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Pneumonia Treatment Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Pneumonia Treatment Drugs Industry Trends Table 2. Pneumonia Treatment Drugs Industry Drivers Table 3. Pneumonia Treatment Drugs Industry Opportunities and Challenges Table 4. Pneumonia Treatment Drugs Industry Restraints Table 5. Global Pneumonia Treatment Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Pneumonia Treatment Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Pneumonia Treatment Drugs Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Pneumonia Treatment Drugs Sales Market Share by Manufacturers Table 9. Global Pneumonia Treatment Drugs Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Pneumonia Treatment Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Pneumonia Treatment Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Pneumonia Treatment Drugs Manufacturers, Product Type & Application Table 13. Global Pneumonia Treatment Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Pneumonia Treatment Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Vaccines Table 17. Major Manufacturers of Vancomycin Table 18. Major Manufacturers of Cephalosporin Table 19. Major Manufacturers of Tetracyclines Table 20. Major Manufacturers of Penicillin Table 21. Major Manufacturers of Other Antibiotics Table 22. Major Manufacturers of Immunotherapy Drug Table 23. Major Manufacturers of Interferon Table 24. Major Manufacturers of Fluoroquinolones Table 25. Major Manufacturers of Macrolides Table 26. Global Pneumonia Treatment Drugs Sales by Type 2021 VS 2025 VS 2032 (k units) Table 27. Global Pneumonia Treatment Drugs Sales by Type (2021-2026) & (k units) Table 28. Global Pneumonia Treatment Drugs Sales by Type (2027-2032) & (k units) Table 29. Global Pneumonia Treatment Drugs Sales Market Share by Type (2021-2026) Table 30. Global Pneumonia Treatment Drugs Sales Market Share by Type (2027-2032) Table 31. Global Pneumonia Treatment Drugs Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 32. Global Pneumonia Treatment Drugs Revenue by Type (2021-2026) & (k units) Table 33. Global Pneumonia Treatment Drugs Revenue by Type (2027-2032) & (k units) Table 34. Global Pneumonia Treatment Drugs Revenue Market Share by Type (2021-2026) Table 35. Global Pneumonia Treatment Drugs Revenue Market Share by Type (2027-2032) Table 36. Major Manufacturers of Hospital Table 37. Major Manufacturers of Clinic Table 38. Major Manufacturers of Drugstore Table 39. Global Pneumonia Treatment Drugs Sales by Application 2021 VS 2025 VS 2032 (k units) Table 40. Global Pneumonia Treatment Drugs Sales by Application (2021-2026) & (k units) Table 41. Global Pneumonia Treatment Drugs Sales by Application (2027-2032) & (k units) Table 42. Global Pneumonia Treatment Drugs Sales Market Share by Application (2021-2026) Table 43. Global Pneumonia Treatment Drugs Sales Market Share by Application (2027-2032) Table 44. Global Pneumonia Treatment Drugs Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 45. Global Pneumonia Treatment Drugs Revenue by Application (2021-2026) & (k units) Table 46. Global Pneumonia Treatment Drugs Revenue by Application (2027-2032) & (k units) Table 47. Global Pneumonia Treatment Drugs Revenue Market Share by Application (2021-2026) Table 48. Global Pneumonia Treatment Drugs Revenue Market Share by Application (2027-2032) Table 49. Global Pneumonia Treatment Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 50. Global Pneumonia Treatment Drugs Sales by Region (2021-2026) & (k units) Table 51. Global Pneumonia Treatment Drugs Sales Market Share by Region (2021-2026) Table 52. Global Pneumonia Treatment Drugs Sales Forecasted by Region (2027-2032) & (k units) Table 53. Global Pneumonia Treatment Drugs Sales Forecasted Market Share by Region (2027-2032) Table 54. North America Pneumonia Treatment Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. North America Pneumonia Treatment Drugs Sales by Country (2021-2026) & (k units) Table 56. North America Pneumonia Treatment Drugs Sales by Country (2027-2032) & (k units) Table 57. Europe Pneumonia Treatment Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Europe Pneumonia Treatment Drugs Sales by Country (2021-2026) & (k units) Table 59. Europe Pneumonia Treatment Drugs Sales by Country (2027-2032) & (k units) Table 60. Asia Pacific Pneumonia Treatment Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 61. Asia Pacific Pneumonia Treatment Drugs Sales by Country (2021-2026) & (k units) Table 62. Asia Pacific Pneumonia Treatment Drugs Sales by Country (2027-2032) & (k units) Table 63. South America, Middle East and Africa Pneumonia Treatment Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 64. South America, Middle East and Africa Pneumonia Treatment Drugs Sales by Country (2021-2026) & (k units) Table 65. South America, Middle East and Africa Pneumonia Treatment Drugs Sales by Country (2027-2032) & (k units) Table 66. Global Pneumonia Treatment Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 67. Global Pneumonia Treatment Drugs Revenue by Region (2021-2026) & (US$ Million) Table 68. Global Pneumonia Treatment Drugs Revenue by Region (2027-2032) & (US$ Million) Table 69. Global Pneumonia Treatment Drugs Revenue Market Share by Region (2021-2026) Table 70. Global Pneumonia Treatment Drugs Revenue Market Share by Region (2027-2032) Table 71. Teva Pharmaceutical Company Information Table 72. Teva Pharmaceutical Business Overview Table 73. Teva Pharmaceutical Pneumonia Treatment Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Teva Pharmaceutical Pneumonia Treatment Drugs Product Portfolio Table 75. Teva Pharmaceutical Recent Development Table 76. Sun Pharmaceutical Company Information Table 77. Sun Pharmaceutical Business Overview Table 78. Sun Pharmaceutical Pneumonia Treatment Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Sun Pharmaceutical Pneumonia Treatment Drugs Product Portfolio Table 80. Sun Pharmaceutical Recent Development Table 81. Novartis Company Information Table 82. Novartis Business Overview Table 83. Novartis Pneumonia Treatment Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Novartis Pneumonia Treatment Drugs Product Portfolio Table 85. Novartis Recent Development Table 86. Mylan Company Information Table 87. Mylan Business Overview Table 88. Mylan Pneumonia Treatment Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Mylan Pneumonia Treatment Drugs Product Portfolio Table 90. Mylan Recent Development Table 91. Pfizer Company Information Table 92. Pfizer Business Overview Table 93. Pfizer Pneumonia Treatment Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Pfizer Pneumonia Treatment Drugs Product Portfolio Table 95. Pfizer Recent Development Table 96. GlaxoSmithKline Company Information Table 97. GlaxoSmithKline Business Overview Table 98. GlaxoSmithKline Pneumonia Treatment Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. GlaxoSmithKline Pneumonia Treatment Drugs Product Portfolio Table 100. GlaxoSmithKline Recent Development Table 101. AstraZeneca Company Information Table 102. AstraZeneca Business Overview Table 103. AstraZeneca Pneumonia Treatment Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. AstraZeneca Pneumonia Treatment Drugs Product Portfolio Table 105. AstraZeneca Recent Development Table 106. Theravance Biopharma Company Information Table 107. Theravance Biopharma Business Overview Table 108. Theravance Biopharma Pneumonia Treatment Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Theravance Biopharma Pneumonia Treatment Drugs Product Portfolio Table 110. Theravance Biopharma Recent Development Table 111. Shinogi Company Information Table 112. Shinogi Business Overview Table 113. Shinogi Pneumonia Treatment Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Shinogi Pneumonia Treatment Drugs Product Portfolio Table 115. Shinogi Recent Development Table 116. MSD Company Information Table 117. MSD Business Overview Table 118. MSD Pneumonia Treatment Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. MSD Pneumonia Treatment Drugs Product Portfolio Table 120. MSD Recent Development Table 121. Medicines Company Information Table 122. Medicines Business Overview Table 123. Medicines Pneumonia Treatment Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Medicines Pneumonia Treatment Drugs Product Portfolio Table 125. Medicines Recent Development Table 126. Combioxin Company Information Table 127. Combioxin Business Overview Table 128. Combioxin Pneumonia Treatment Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Combioxin Pneumonia Treatment Drugs Product Portfolio Table 130. Combioxin Recent Development Table 131. Arsanis Company Information Table 132. Arsanis Business Overview Table 133. Arsanis Pneumonia Treatment Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Arsanis Pneumonia Treatment Drugs Product Portfolio Table 135. Arsanis Recent Development Table 136. Key Raw Materials Table 137. Raw Materials Key Suppliers Table 138. Pneumonia Treatment Drugs Distributors List Table 139. Pneumonia Treatment Drugs Customers List Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. Pneumonia Treatment Drugs Product Image Figure 2. Global Pneumonia Treatment Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pneumonia Treatment Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Pneumonia Treatment Drugs Sales (2021-2032) & (k units) Figure 5. Global Pneumonia Treatment Drugs Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Pneumonia Treatment Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Vaccines Image Figure 9. Vancomycin Image Figure 10. Cephalosporin Image Figure 11. Tetracyclines Image Figure 12. Penicillin Image Figure 13. Other Antibiotics Image Figure 14. Immunotherapy Drug Image Figure 15. Interferon Image Figure 16. Fluoroquinolones Image Figure 17. Macrolides Image Figure 18. Global Pneumonia Treatment Drugs Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 19. Global Pneumonia Treatment Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Pneumonia Treatment Drugs Sales Market Share by Type (2021-2032) Figure 21. Global Pneumonia Treatment Drugs Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Pneumonia Treatment Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Pneumonia Treatment Drugs Revenue Market Share by Type (2021-2032) Figure 24. Hospital Image Figure 25. Clinic Image Figure 26. Drugstore Image Figure 27. Global Pneumonia Treatment Drugs Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 28. Global Pneumonia Treatment Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 29. Global Pneumonia Treatment Drugs Sales Market Share by Application (2021-2032) Figure 30. Global Pneumonia Treatment Drugs Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 31. Global Pneumonia Treatment Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 32. Global Pneumonia Treatment Drugs Revenue Market Share by Application (2021-2032) Figure 33. North America Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 34. North America Pneumonia Treatment Drugs Sales Market Share by Country (2021-2032) Figure 35. U.S. Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 36. Canada Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 37. Mexico Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 38. Europe Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 39. Europe Pneumonia Treatment Drugs Sales Market Share by Country (2021-2032) Figure 40. Germany Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 41. France Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 42. U.K. Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 43. Italy Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 44. Netherlands Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 45. Asia Pacific Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 46. Asia Pacific Pneumonia Treatment Drugs Sales Market Share by Country (2021-2032) Figure 47. China Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 48. Japan Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Korea Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 50. Southeast Asia Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 51. India Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 52. Australia Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 53. South America, Middle East and Africa Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 54. South America, Middle East and Africa Pneumonia Treatment Drugs Sales Market Share by Country (2021-2032) Figure 55. Brazil Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 56. South Africa Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 57. Saudi Arabia Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 58. Turkey Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 59. Argentina Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 60. UAE Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 61. Egypt Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 62. Chile Pneumonia Treatment Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 63. Global Pneumonia Treatment Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Global Pneumonia Treatment Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 65. North America Pneumonia Treatment Drugs Revenue (2021-2032) & (US$ Million) Figure 66. North America Pneumonia Treatment Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Europe Pneumonia Treatment Drugs Revenue (2021-2032) & (US$ Million) Figure 68. Europe Pneumonia Treatment Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Asia-Pacific Pneumonia Treatment Drugs Revenue (2021-2032) & (US$ Million) Figure 70. Asia-Pacific Pneumonia Treatment Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. South America, Middle East and Africa Pneumonia Treatment Drugs Revenue (2021-2032) & (US$ Million) Figure 72. South America, Middle East and Africa Pneumonia Treatment Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 73. Pneumonia Treatment Drugs Value Chain Figure 74. Manufacturing Cost Structure Figure 75. Pneumonia Treatment Drugs Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Years Considered Figure 79. Research Process Figure 80. Key Executives Interviewed

Scope & coverage.

Types
  • Vaccines
  • Vancomycin
  • Cephalosporin
  • Tetracyclines
  • Penicillin
  • Other Antibiotics
  • Immunotherapy Drug
  • Interferon
  • Fluoroquinolones
  • Macrolides
Applications
  • Hospital
  • Clinic
  • Drugstore
Companies covered
  • Teva Pharmaceutical
  • Sun Pharmaceutical
  • Novartis
  • Mylan
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Theravance Biopharma
  • Shinogi
  • MSD
  • Medicines
  • Combioxin
  • Arsanis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pneumonia Treatment Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pneumonia Treatment Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Pneumonia Treatment Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Pneumonia Treatment Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Pneumonia Treatment Drugs Market Dynamics
  1. 2.1 Pneumonia Treatment Drugs Industry Trends
  2. 2.2 Pneumonia Treatment Drugs Industry Drivers
  3. 2.3 Pneumonia Treatment Drugs Industry Opportunities and Challenges
  4. 2.4 Pneumonia Treatment Drugs Industry Restraints
3 Pneumonia Treatment Drugs Market by Manufacturers
  1. 3.1 Global Pneumonia Treatment Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Pneumonia Treatment Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Pneumonia Treatment Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Pneumonia Treatment Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pneumonia Treatment Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Pneumonia Treatment Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Pneumonia Treatment Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pneumonia Treatment Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pneumonia Treatment Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pneumonia Treatment Drugs Tier 1, Tier 2, and Tier 3
4 Pneumonia Treatment Drugs Market by Type
  1. 4.1 Pneumonia Treatment Drugs Type Introduction
  2. 4.1.1 Vaccines
  3. 4.1.2 Vancomycin
  4. 4.1.3 Cephalosporin
  5. 4.1.4 Tetracyclines
  6. 4.1.5 Penicillin
  7. 4.1.6 Other Antibiotics
  8. 4.1.7 Immunotherapy Drug
  9. 4.1.8 Interferon
  10. 4.1.9 Fluoroquinolones
  11. 4.1.10 Macrolides
  12. 4.2 Global Pneumonia Treatment Drugs Sales by Type
  13. 4.2.1 Global Pneumonia Treatment Drugs Sales by Type (2021 VS 2025 VS 2032)
  14. 4.2.2 Global Pneumonia Treatment Drugs Sales by Type (2021-2032)
  15. 4.2.3 Global Pneumonia Treatment Drugs Sales Market Share by Type (2021-2032)
  16. 4.3 Global Pneumonia Treatment Drugs Revenue by Type
  17. 4.3.1 Global Pneumonia Treatment Drugs Revenue by Type (2021 VS 2025 VS 2032)
  18. 4.3.2 Global Pneumonia Treatment Drugs Revenue by Type (2021-2032)
  19. 4.3.3 Global Pneumonia Treatment Drugs Revenue Market Share by Type (2021-2032)
5 Pneumonia Treatment Drugs Market by Application
  1. 5.1 Pneumonia Treatment Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Drugstore
  5. 5.2 Global Pneumonia Treatment Drugs Sales by Application
  6. 5.2.1 Global Pneumonia Treatment Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pneumonia Treatment Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Pneumonia Treatment Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Pneumonia Treatment Drugs Revenue by Application
  10. 5.3.1 Global Pneumonia Treatment Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Pneumonia Treatment Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Pneumonia Treatment Drugs Revenue Market Share by Application (2021-2032)
6 Global Pneumonia Treatment Drugs Sales by Region
  1. 6.1 Global Pneumonia Treatment Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pneumonia Treatment Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Pneumonia Treatment Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Pneumonia Treatment Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pneumonia Treatment Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Pneumonia Treatment Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Pneumonia Treatment Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Pneumonia Treatment Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Pneumonia Treatment Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Pneumonia Treatment Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Pneumonia Treatment Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Pneumonia Treatment Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Pneumonia Treatment Drugs Revenue by Region
  1. 7.1 Global Pneumonia Treatment Drugs Revenue by Region
  2. 7.1.1 Global Pneumonia Treatment Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Pneumonia Treatment Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Pneumonia Treatment Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Pneumonia Treatment Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Pneumonia Treatment Drugs Revenue (2021-2032)
  8. 7.2.2 North America Pneumonia Treatment Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Pneumonia Treatment Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Pneumonia Treatment Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Pneumonia Treatment Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Pneumonia Treatment Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Pneumonia Treatment Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Pneumonia Treatment Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical
  2. 8.1.1 Teva Pharmaceutical Company Information
  3. 8.1.2 Teva Pharmaceutical Business Overview
  4. 8.1.3 Teva Pharmaceutical Pneumonia Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Pneumonia Treatment Drugs Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Recent Developments
  7. 8.2 Sun Pharmaceutical
  8. 8.2.1 Sun Pharmaceutical Company Information
  9. 8.2.2 Sun Pharmaceutical Business Overview
  10. 8.2.3 Sun Pharmaceutical Pneumonia Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sun Pharmaceutical Pneumonia Treatment Drugs Product Portfolio
  12. 8.2.5 Sun Pharmaceutical Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Pneumonia Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Pneumonia Treatment Drugs Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Mylan
  20. 8.4.1 Mylan Company Information
  21. 8.4.2 Mylan Business Overview
  22. 8.4.3 Mylan Pneumonia Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mylan Pneumonia Treatment Drugs Product Portfolio
  24. 8.4.5 Mylan Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Pneumonia Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Pneumonia Treatment Drugs Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 GlaxoSmithKline
  32. 8.6.1 GlaxoSmithKline Company Information
  33. 8.6.2 GlaxoSmithKline Business Overview
  34. 8.6.3 GlaxoSmithKline Pneumonia Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline Pneumonia Treatment Drugs Product Portfolio
  36. 8.6.5 GlaxoSmithKline Recent Developments
  37. 8.7 AstraZeneca
  38. 8.7.1 AstraZeneca Company Information
  39. 8.7.2 AstraZeneca Business Overview
  40. 8.7.3 AstraZeneca Pneumonia Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Pneumonia Treatment Drugs Product Portfolio
  42. 8.7.5 AstraZeneca Recent Developments
  43. 8.8 Theravance Biopharma
  44. 8.8.1 Theravance Biopharma Company Information
  45. 8.8.2 Theravance Biopharma Business Overview
  46. 8.8.3 Theravance Biopharma Pneumonia Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Theravance Biopharma Pneumonia Treatment Drugs Product Portfolio
  48. 8.8.5 Theravance Biopharma Recent Developments
  49. 8.9 Shinogi
  50. 8.9.1 Shinogi Company Information
  51. 8.9.2 Shinogi Business Overview
  52. 8.9.3 Shinogi Pneumonia Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Shinogi Pneumonia Treatment Drugs Product Portfolio
  54. 8.9.5 Shinogi Recent Developments
  55. 8.10 MSD
  56. 8.10.1 MSD Company Information
  57. 8.10.2 MSD Business Overview
  58. 8.10.3 MSD Pneumonia Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 MSD Pneumonia Treatment Drugs Product Portfolio
  60. 8.10.5 MSD Recent Developments
  61. 8.11 Medicines
  62. 8.11.1 Medicines Company Information
  63. 8.11.2 Medicines Business Overview
  64. 8.11.3 Medicines Pneumonia Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Medicines Pneumonia Treatment Drugs Product Portfolio
  66. 8.11.5 Medicines Recent Developments
  67. 8.12 Combioxin
  68. 8.12.1 Combioxin Company Information
  69. 8.12.2 Combioxin Business Overview
  70. 8.12.3 Combioxin Pneumonia Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Combioxin Pneumonia Treatment Drugs Product Portfolio
  72. 8.12.5 Combioxin Recent Developments
  73. 8.13 Arsanis
  74. 8.13.1 Arsanis Company Information
  75. 8.13.2 Arsanis Business Overview
  76. 8.13.3 Arsanis Pneumonia Treatment Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Arsanis Pneumonia Treatment Drugs Product Portfolio
  78. 8.13.5 Arsanis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pneumonia Treatment Drugs Value Chain Analysis
  2. 9.1.1 Pneumonia Treatment Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pneumonia Treatment Drugs Production Mode & Process
  6. 9.2 Pneumonia Treatment Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pneumonia Treatment Drugs Distributors
  9. 9.2.3 Pneumonia Treatment Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst